Esomeprazole potassium salt

Research use only, not for human use.

A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells.

A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells; the (S)-(?)-enantiomer of omeprazole for treatment of dyspepsia, peptic ulcer disease, and gastroesophageal reflux disease.Ulcer Approved.

Esomeprazole (25-100 μM; 20 hours; MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification. Cell Viability AssayCell Line:MDA-MB-468 cells Concentration:25 μM, 50 μM, 75 μM, 100 μM Incubation Time:20 hours Result:Suppressed growth of triple-negative breast cancer cell in vitro in a dose-dependent manner.

Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis. Animal Model:C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury Dosage:30 mg/kg, 300 mg/kg Administration:Oral gavage; daily; for 19 or 11 days Result:Significantly inhibited the progression of fibrosis throughout the lungs of the animals.

S)-Omeprazole potassium

Membrane Transporter/Ion Channel

Proton Pump

Proton Pump

Other Indications

Ulcer

161796-84-5

383.5064

C17H18KN3O3S

>98% (HPLC)

10 mM in DMSO

CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC.[K+]

1H-Benzimidazole, 6-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, potassium salt (1:1)

(-20℃)

With Ice Pack

≥ 2 years